Life sciences & health care M&A update: Q3 2018

The life sciences and health care industry has historically faced challenges when it comes to drug development and its complex processes. Master Protocol, a new streamlined and time-effective process may be a solution to help address the slow drug development process. This life sciences and health care mergers and acquisitions (M&A) update provides Deloitte Corporate Finance LLC insights and market data analysis that shed light on M&A trends in the life sciences and health care industry.

Challenges facing drug development

As biopharma companies face challenges regarding the slow process of drug development, many have begun to implement the process known as Master Protocol, in-order-to answer multiple questions within a drug development phase in a shorter amount of time.1

Potential benefits of Master Protocols2

  • Streamlines logistics: Multiple stakeholders can come together to collect, synthesize, and analyze various treatment combinations and effects of competing drugs.
  • Reduces cost and cycle time: Reduces pharma companies’ time to activation, which helps alleviate the cost barrier facing the current model of drug development.
  • Continuous learning: Successful collaborative groups can work together to share knowledge about the effectiveness of a certain therapy, or a certain group of therapies, on a specific disease.

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.


1 Deloitte Center for Health Solutions (DCHS). Master Protocol Clinical Trial Drug Development Process. October 2018.

2 Ibid.

Did you find this useful?